Google DeepMind announced that its agent development platform, Google Antigravity, is accelerating the discovery of novel antimicrobial peptides (AMPs) to combat the growing issue of antibiotic resistance. The platform, which integrates the ProtNLM deep learning model, can rapidly screen millions of uncharacterized protein sequences. It has already successfully identified a novel AMP candidate with predicted activity against respiratory infection pathogens, which is currently undergoing wet lab validation. This technology aims to streamline the drug discovery process by consolidating previously fragmented database searches into a single session and leveraging AI agents for structural evaluation and literature synthesis to address a global health crisis.